Bronchogen

Bronchogen is a short peptide from the Khavinson family of "peptide bioregulators" developed at the Saint Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson. The Khavinson group's broader theoretical framework holds that very short peptides (typically 2-4 amino acids) derived from tissue extracts can act as tissue-specific gene-expression modulators, selectively binding to DNA promoter regions in cells of the originating tissue and thereby restoring more youthful gene expression patterns. Bronchogen is the bronchial-tissue-targeting member of this family, developed for use in chronic obstructive bronchial conditions including chronic bronchitis, COPD, and asthma adjunct therapy.

In Russian clinical use, Bronchogen has been employed both as an injectable and as an oral formulation (sometimes referred to as Bronchorestin in the oral form) for restoration of bronchial epithelial function in patients with chronic respiratory disease. Russian clinical-observational studies have reported improvements in pulmonary function, reduction in exacerbation frequency, and improvements in subjective dyspnea and exercise tolerance.

Western clinical literature on Bronchogen specifically is essentially absent. The compound forms part of a broader family of Khavinson bioregulators that have an extensive Russian clinical track record but very limited independent Western validation. Research-chemical vendors sell the peptide for research and self-experimentation contexts.

Bronchogen was developed in the late 1990s / early 2000s as part of the Khavinson group's systematic program of identifying tissue-specific short-peptide bioregulators. The general approach — isolation of bioactive peptide fractions from bovine tissue extracts, identification of the active short-peptide sequences, then synthesis of those peptides for clinical use — produced a series of organ-specific bioregulators including Bronchogen. The compound entered Russian clinical practice in the 2000s.